{"id":132703,"date":"2026-06-26T18:01:57","date_gmt":"2026-06-26T12:31:57","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=132703"},"modified":"2026-06-26T18:01:58","modified_gmt":"2026-06-26T12:31:58","slug":"wanbury-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/","title":{"rendered":"Wanbury Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Wanbury share price target 2026 is Rs 330, implying approximately 20 percent upside from the current market price of Rs 274.35 (NSE: WANBURY). With Q4 FY26 results released in 2026 and API Pharmaceuticals and Formulations tailwinds in focus, the Rs 330 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/wanbury\/wanbury-ltd-share-price-today\">Wanbury<\/a> (NSE: WANBURY) is a API Pharmaceuticals and Formulations company trading at Rs 274.35 with a market capitalisation of Rs 958 crore. Analysts have set the <strong>Wanbury share price target<\/strong> at Rs 330 for 2026, based on FY27 earnings projections and sector re-rating potential. According to Ankit Jaiswal, Senior Research Analyst at Univest, the Rs 330 price objective reflects improving fundamentals in the API Pharmaceuticals and Formulations space. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=wanbury\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Wanbury_Share_Price_Target_2026_Key_Takeaways\" title=\"Wanbury Share Price Target 2026: Key Takeaways\">Wanbury Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Wanbury_Company_Overview\" title=\"Wanbury Company Overview\">Wanbury Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Why_Is_the_Wanbury_Share_Price_Target_Set_at_Rs_330_for_2026\" title=\"Why Is the Wanbury Share Price Target Set at Rs 330 for 2026\">Why Is the Wanbury Share Price Target Set at Rs 330 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Structural_Sector_Tailwinds_in_API_Pharmaceuticals_and_Formulations\" title=\"Structural Sector Tailwinds in API Pharmaceuticals and Formulations\">Structural Sector Tailwinds in API Pharmaceuticals and Formulations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Wanbury_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Wanbury Share Price Targets: Short Term, 12 Month, and Long Term\">Wanbury Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Short_Term_Wanbury_Share_Price_Target\" title=\"Short Term Wanbury Share Price Target\">Short Term Wanbury Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#12-Month_Wanbury_Share_Price_Target_2026\" title=\"12-Month Wanbury Share Price Target 2026\">12-Month Wanbury Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Long_Term_Wanbury_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Wanbury Share Price Target: FY27 to FY28\">Long Term Wanbury Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_Wanbury_in_2026\" title=\"Bull Case and Bear Case Scenarios for Wanbury in 2026\">Bull Case and Bear Case Scenarios for Wanbury in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Bull_Case_Wanbury_Share_Price_Target_Rs_400\" title=\"Bull Case Wanbury Share Price Target: Rs 400\">Bull Case Wanbury Share Price Target: Rs 400<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Bear_Case_Wanbury_Share_Price_Target_Rs_220\" title=\"Bear Case Wanbury Share Price Target: Rs 220\">Bear Case Wanbury Share Price Target: Rs 220<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_Wanbury_2026_Price_Objective\" title=\"Key Risks That Could Derail the Wanbury 2026 Price Objective\">Key Risks That Could Derail the Wanbury 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Competitive_Intensity_Among_API_Pharmaceuticals_and_Formulations_Peers\" title=\"Competitive Intensity Among API Pharmaceuticals and Formulations Peers\">Competitive Intensity Among API Pharmaceuticals and Formulations Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#How_to_Invest_in_Wanbury\" title=\"How to Invest in Wanbury\">How to Invest in Wanbury<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#FAQs_on_Wanbury_Share_Price_Target_2026\" title=\"FAQs on Wanbury Share Price Target 2026\">FAQs on Wanbury Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_is_the_Wanbury_share_price_target_for_2026\" title=\"What is the Wanbury share price target for 2026?\">What is the Wanbury share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_was_the_Wanbury_share_price_target_for_2025\" title=\"What was the Wanbury share price target for 2025?\">What was the Wanbury share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#Is_Wanbury_a_good_investment_at_Rs_27435\" title=\"Is Wanbury a good investment at Rs 274.35?\">Is Wanbury a good investment at Rs 274.35?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_are_the_key_risks_to_the_Wanbury_share_price_target_2026\" title=\"What are the key risks to the Wanbury share price target 2026?\">What are the key risks to the Wanbury share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Wanbury\" title=\"What is the 52 week high and low of Wanbury?\">What is the 52 week high and low of Wanbury?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_Wanbury_in_2026\" title=\"What are the main growth catalysts for Wanbury in 2026?\">What are the main growth catalysts for Wanbury in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#How_does_Wanbury_compare_to_its_peers\" title=\"How does Wanbury compare to its peers?\">How does Wanbury compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/wanbury-share-price-target-2026\/#What_is_the_Wanbury_share_price_target_for_2027\" title=\"What is the Wanbury share price target for 2027?\">What is the Wanbury share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Wanbury_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Wanbury Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Wanbury share price target 2026:<\/strong> Rs 330 (20% upside from CMP Rs 274.35)<\/li>\n<li><strong>Bull case:<\/strong> Rs 400 | <strong>Bear case:<\/strong> Rs 220<\/li>\n<li><strong>Ticker:<\/strong> WANBURY | <strong>Sector:<\/strong> API Pharmaceuticals and Formulations | <strong>MCap:<\/strong> Rs 958 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 161.5 to Rs 315.2 | <strong>PE:<\/strong> 15x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Wanbury_Company_Overview\"><\/span><strong>Wanbury Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Wanbury (NSE: WANBURY) is a Mumbai-based pharmaceutical company manufacturing active pharmaceutical ingredients including metformin and anti-diabetic APIs along with generic formulations for domestic and global markets. At CMP Rs 274.35 against a 52 week range of Rs 161.5 to Rs 315.2, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 958 crore with trailing PE of 15x. Compared to peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences, Wanbury is positioned as a potential re-rating candidate toward the Rs 330 price objective on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>WANBURY<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>API Pharmaceuticals and Formulations<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 274.35<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 315.2<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 161.5<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 958 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>15x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 330<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 400<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 220<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Wanbury_Share_Price_Target_Set_at_Rs_330_for_2026\"><\/span><strong>Why Is the Wanbury Share Price Target Set at Rs 330 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Wanbury share price target<\/strong> of Rs 330 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Ankit Jaiswal at Univest notes that Q4 FY26 results confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 274.35.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_API_Pharmaceuticals_and_Formulations\"><\/span><strong>Structural Sector Tailwinds in API Pharmaceuticals and Formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The API Pharmaceuticals and Formulations sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Wanbury&#8217;s position among peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 400 bull case to materialise.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Wanbury&#8217;s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 330 analyst consensus.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Wanbury&#8217;s API Pharmaceuticals and Formulations operations, improving the probability of achieving the Rs 330 price objective through FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 15x PE, Wanbury is positioned as a beneficiary of institutional reallocation toward the Rs 400 bull case over the medium term.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Wanbury_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Wanbury Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Wanbury_Share_Price_Target\"><\/span><strong>Short Term Wanbury Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for Wanbury is anchored close to the 52 week low of Rs 161.5. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 274.35.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Wanbury_Share_Price_Target_2026\"><\/span><strong>12-Month Wanbury Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Wanbury share price target 2026<\/strong> is Rs 330, implying approximately 20 percent upside from CMP Rs 274.35. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Wanbury_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Wanbury Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term Wanbury share price target<\/strong> for FY27 to FY28 is Rs 400 in the bull case, requiring full earnings delivery, re-rating among peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences, and sustained institutional buying over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_Wanbury_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for Wanbury in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Wanbury_Share_Price_Target_Rs_400\"><\/span><strong>Bull Case Wanbury Share Price Target: Rs 400<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case Wanbury share price target<\/strong> of Rs 400 materialises when FY27 earnings beat analyst estimates, API Pharmaceuticals and Formulations tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 274.35.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Wanbury_Share_Price_Target_Rs_220\"><\/span><strong>Bear Case Wanbury Share Price Target: Rs 220<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case Wanbury share price target<\/strong> of Rs 220 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 161.5.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 400<\/td>\n<td>FY27 beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 330<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 220<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_Wanbury_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the Wanbury 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the <strong>Wanbury share price target<\/strong> of Rs 330, with FII outflows being the direct transmission mechanism to Indian equity valuations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 330 analyst price objective. Investors must monitor quarterly results and management commentary closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_API_Pharmaceuticals_and_Formulations_Peers\"><\/span><strong>Competitive Intensity Among API Pharmaceuticals and Formulations Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences could compress Wanbury&#8217;s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 330 analyst target for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Wanbury\"><\/span><strong>How to Invest in Wanbury<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>Wanbury share price target<\/strong> of Rs 330, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on API Pharmaceuticals and Formulations sector demand.<\/p>\n<p>Open a Demat account with a SEBI registered stockbroker to trade Wanbury (NSE: WANBURY) with full regulatory protection. Study the competitive landscape among peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences before executing any position.<\/p>\n<p>Plan your entry using the 52 week low of Rs 161.5 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 330 price objective. Always set a stop loss below the 52 week low.<\/p>\n<p>Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Wanbury&#8217;s live share price and receive daily stock recommendations.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Wanbury_Share_Price_Target_2026\"><\/span><strong>FAQs on Wanbury Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Wanbury_share_price_target_for_2026\"><\/span><strong>What is the Wanbury share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Wanbury share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 274.35. Bull case is Rs 400, bear case is Rs 220.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Wanbury_share_price_target_for_2025\"><\/span><strong>What was the Wanbury share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price objective for Wanbury was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 330, reflecting FY27 growth potential from CMP Rs 274.35.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Wanbury_a_good_investment_at_Rs_27435\"><\/span><strong>Is Wanbury a good investment at Rs 274.35?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 274.35, Wanbury offers potential upside toward Rs 330 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Wanbury_share_price_target_2026\"><\/span><strong>What are the key risks to the Wanbury share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Wanbury share price target of Rs 330 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in API Pharmaceuticals and Formulations. Monitoring quarterly results is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Wanbury\"><\/span><strong>What is the 52 week high and low of Wanbury?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Wanbury is Rs 315.2 and the 52 week low is Rs 161.5. At CMP Rs 274.35, the stock offers potential upside toward the Rs 330 price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_Wanbury_in_2026\"><\/span><strong>What are the main growth catalysts for Wanbury in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key catalysts include FY27 PAT recovery, API Pharmaceuticals and Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Wanbury_compare_to_its_peers\"><\/span><strong>How does Wanbury compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Wanbury operates in API Pharmaceuticals and Formulations alongside peers in API pharma like Divi&#8217;s Laboratories and Solara Active Pharma Sciences. At CMP Rs 274.35 with MCap Rs 958 crore, it is a potential re-rating candidate toward the Wanbury share price target of Rs 330 on FY27 delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Wanbury_share_price_target_for_2027\"><\/span><strong>What is the Wanbury share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Wanbury share price target for FY27 to FY28 is Rs 400 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Wanbury share price target for 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Wanbury share price target 2026 is Rs 330, implying approximately 20 percent upside from CMP Rs 274.35. Bull case is Rs 400, bear case is Rs 220.\"}},{\"@type\":\"Question\",\"name\":\"What was the Wanbury share price target for 2025?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 2025 price objective for Wanbury was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 330, reflecting FY27 growth potential from CMP Rs 274.35.\"}},{\"@type\":\"Question\",\"name\":\"Is Wanbury a good investment at Rs 274.35?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"At Rs 274.35, Wanbury offers potential upside toward Rs 330 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.\"}},{\"@type\":\"Question\",\"name\":\"What are the key risks to the Wanbury share price target 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks to the Wanbury share price target of Rs 330 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in API Pharmaceuticals and Formulations. Monitoring quarterly results is essential.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52 week high and low of Wanbury?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 52 week high of Wanbury is Rs 315.2 and the 52 week low is Rs 161.5. At CMP Rs 274.35, the stock offers potential upside toward the Rs 330 price objective.\"}},{\"@type\":\"Question\",\"name\":\"What are the main growth catalysts for Wanbury in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key catalysts include FY27 PAT recovery, API Pharmaceuticals and Formulations tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.\"}},{\"@type\":\"Question\",\"name\":\"How does Wanbury compare to its peers?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Wanbury operates in API Pharmaceuticals and Formulations alongside peers in API pharma like Divi's Laboratories and Solara Active Pharma Sciences. At CMP Rs 274.35 with MCap Rs 958 crore, it is a potential re-rating candidate toward the Wanbury share price target of Rs 330 on FY27 delivery.\"}},{\"@type\":\"Question\",\"name\":\"What is the Wanbury share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The long-term Wanbury share price target for FY27 to FY28 is Rs 400 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Wanbury share price target 2026 is Rs 330, ~20% upside from CMP Rs 274.35. Bull Rs 400, bear Rs 220. 2026.<\/p>\n","protected":false},"author":35,"featured_media":133467,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-132703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782477122:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Wanbury Share Price Target 2026"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Wanbury Share Price Target 2026: Rs 330 Analyst Forecast"],"rank_math_description":["The Wanbury share price target 2026 is Rs 330, ~20% upside from CMP Rs 274.35. Bull Rs 400, bear Rs 220. 2026."],"_thumbnail_id":["133467"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21799"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Wanbury-Share-Price-Target-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/132703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=132703"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/132703\/revisions"}],"predecessor-version":[{"id":133468,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/132703\/revisions\/133468"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/133467"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=132703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=132703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=132703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}